Neurocrine Biosciences
NBIX
NBIX
332 hedge funds and large institutions have $8.09B invested in Neurocrine Biosciences in 2019 Q3 according to their latest regulatory filings, with 64 funds opening new positions, 122 increasing their positions, 106 reducing their positions, and 32 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
more capital invested
Capital invested by funds: $ → $
6% more call options, than puts
Call options by funds: $61.4M | Put options by funds: $58.1M
0.57% more ownership
Funds ownership: 97.45% → 98.02% (+0.57%)
13% less funds holding in top 10
Funds holding in top 10: 8 → 7 (-1)
Holders
332
Holding in Top 10
7
Calls
$61.4M
Puts
$58.1M
Top Buyers
| 1 | +$302M | |
| 2 | +$46.8M | |
| 3 | +$46M | |
| 4 |
BlackRock
New York
|
+$25M |
| 5 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$18.9M |
Top Sellers
| 1 | -$98.7M | |
| 2 | -$79.1M | |
| 3 | -$76.5M | |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$52M |
| 5 |
First Trust Advisors
Wheaton,
Illinois
|
-$50.2M |